Overview

Cancer is ubiquitous and despite medical advances, remains among the leading causes of death worldwide. Nearly all modern cancer treatments, including chemotherapy and immunotherapy, focus on de-bulking tumors without targeting the most dangerous cells in the tumor: cancer stem cells.

The discovery of cancer stem cells provides an incredible opportunity to merge the fields of oncology and embryonic stem cell biology. The Remedy Plan approach is based on the idea that we should be targeting what makes cancer so dangerous – the embryonic-like properties of cancer stem cells that form the basis for cancer growth, spread, and resistance— so we can develop effective and non-toxic therapies.

Therapies that can both diminish tumor bulk and disrupt cancer stem cells will revolutionize cancer treatment.

Why haven't there been vast improvements in treating cancer yet?

Cancer stem cells are responsible for the spread of cancer cells throughout the body, the growth of tumors, cancer’s resistance to chemotherapy, and the recurrence of tumors after treatment or surgical removal. Because current treatments do not target the cancer stem cell population, they frequently lead to the rise of resistant tumors and continued cancer spread.

Remedy Plan's approach is different from traditional cancer therapies

Remedy Plan is developing drugs that target cancer stem cells to inhibit tumor growth and proliferation. With our proprietary drug screening platform, we are able to quickly screen and identify panels of drug candidates that disrupt cancer stem cells.

Remedy Plan’s drugs will be much more effective than traditional treatments in decreasing tumor growth, prolonging life, and preventing metastasis and recurrence. And because the reactivation of embryonic-like properties is a characteristic shared by many kinds of tumors, cancer containment therapy is expected to be effective on many different types of cancer, including cancer of the colon, stomach, prostate, testicles, breast, and blood.